{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:27:25Z","timestamp":1790807245347,"version":"4.1.0"},"reference-count":107,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Klebsiella pneumoniae is a major cause of hospital-acquired pneumonia and a critical global threat due to its escalating multidrug resistance. This review highlights current advancements in therapeutic strategies, including double and triple drug combinations, and evaluates their clinical efficacy and limitations. We discuss the global dissemination of resistance determinants such as blaKPC, blaNDM and mcr genes, and the complex mechanisms, including porin mutations, efflux pump overexpression and enzymatic degradation. The regional variation in these mechanisms undermines treatment success. Evidence for antibiotic combination therapy, including the double (colistin\/meropenem) and triple (polymyxin B\/meropenem\/rifampicin) regimens, is analysed, along with controversies regarding their superiority over monotherapy. Finally, we highlight inhaled antibiotic delivery, particularly dry powder inhalers, as a promising strategy to achieve targeted, effective pulmonary drug concentrations and reduced systemic toxicity. Despite progress, significant barriers remain, including formulation stability, regulatory hurdles and the continued shortage of clinical trials. Future research should prioritize optimizing inhaled drug therapies and innovative delivery platforms to combat multidrug-resistant K. pneumoniae lung infections.<\/jats:p>","DOI":"10.1093\/jac\/dkag064","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T12:26:46Z","timestamp":1770726406000},"source":"Crossref","is-referenced-by-count":6,"title":["Combating multidrug-resistant\n                    <i>Klebsiella pneumoniae<\/i>\n                    : current therapeutic regimens and future directions"],"prefix":"10.1093","volume":"81","author":[{"given":"Robiul","family":"Islam","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, Faculty of Biomedical Sciences, University of Otago , Dunedin 9054 ,","place":["New Zealand"]},{"name":"School of Pharmacy, Faculty of Health Professional Programmes, University of Otago , Dunedin 9054 ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyamal C","family":"Das","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Faculty of Health Professional Programmes, University of Otago , Dunedin 9054 ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pletzer","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Faculty of Biomedical Sciences, University of Otago , Dunedin 9054 ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"key":"2026022412250202000_dkag064-B1","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1128\/CMR.11.4.589","article-title":"Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors","volume":"11","author":"Podschun","year":"1998","journal-title":"Clin Microbiol Rev"},{"key":"2026022412250202000_dkag064-B2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/femsre\/fuy043","article-title":"Klebsiella pneumoniae infection biology: living to counteract host defences","volume":"43","author":"Bengoechea","year":"2019","journal-title":"FEMS Microbiol Rev"},{"key":"2026022412250202000_dkag064-B3","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1128\/MMBR.00078-15","article-title":"Klebsiella pneumoniae: going on the offense with a strong defense","volume":"80","author":"Paczosa","year":"2016","journal-title":"Microbiol Mol Biol Rev"},{"key":"2026022412250202000_dkag064-B4","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"2026022412250202000_dkag064-B5","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.chest.2019.10.006","article-title":"Rate and predictors of bacteremia in afebrile community-acquired pneumonia","volume":"157","author":"Forstner","year":"2020","journal-title":"Chest"},{"key":"2026022412250202000_dkag064-B6","doi-asserted-by":"publisher","first-page":"20230707","DOI":"10.1515\/med-2023-0707","article-title":"Characteristics of antibiotic resistance mechanisms and genes of Klebsiella pneumoniae","volume":"18","author":"Li","year":"2023","journal-title":"Open Med"},{"key":"2026022412250202000_dkag064-B7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/phar.1537","article-title":"Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use","volume":"35","author":"Bergen","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2026022412250202000_dkag064-B8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s44259-024-00047-2","article-title":"Drug combinations targeting antibiotic resistance","volume":"2","author":"Bogn\u00e1r","year":"2024","journal-title":"NPJ Antimicrob Resist"},{"key":"2026022412250202000_dkag064-B9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European Society of Intensive Care Medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"2026022412250202000_dkag064-B10","doi-asserted-by":"publisher","first-page":"127701","DOI":"10.1016\/j.micres.2024.127701","article-title":"Antibiotic heteroresistance in Klebsiella pneumoniae: definition, detection methods, mechanisms, and combination therapy","volume":"283","author":"Lin","year":"2024","journal-title":"Microbiol Res"},{"key":"2026022412250202000_dkag064-B11","doi-asserted-by":"publisher","first-page":"1352339","DOI":"10.3389\/fcimb.2024.1352339","article-title":"Using host-mimicking conditions and a murine cutaneous abscess model to identify synergistic antibiotic combinations effective against Pseudomonas aeruginosa","volume":"14","author":"Lyons","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"2026022412250202000_dkag064-B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2026022412250202000_dkag064-B13","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3390\/antibiotics10070781","article-title":"Synergistic meropenem\/vaborbactam plus fosfomycin treatment of KPC producing K. pneumoniae septic thrombosis unresponsive to ceftazidime\/avibactam: from the bench to the bedside","volume":"10","author":"Oliva","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2026022412250202000_dkag064-B14","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/jac\/dku027","article-title":"Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections","volume":"69","author":"Oliva","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2026022412250202000_dkag064-B15","doi-asserted-by":"publisher","first-page":"e1007084","DOI":"10.1371\/journal.ppat.1007084","article-title":"Synergy between conventional antibiotics and anti-biofilm peptides in a murine, sub-cutaneous abscess model caused by recalcitrant ESKAPE pathogens","volume":"14","author":"Pletzer","year":"2018","journal-title":"PLoS Pathog"},{"key":"2026022412250202000_dkag064-B16","doi-asserted-by":"publisher","first-page":"e27984","DOI":"10.1016\/j.heliyon.2024.e27984","article-title":"Unraveling resistance mechanisms in combination therapy: a comprehensive review of recent advances and future directions","volume":"10","author":"Morales-Dur\u00e1n","year":"2024","journal-title":"Heliyon"},{"key":"2026022412250202000_dkag064-B17","doi-asserted-by":"publisher","first-page":"107661","DOI":"10.1016\/j.rmed.2024.107661","article-title":"Inhaled antibiotics: a promising drug delivery strategies for efficient treatment of lower respiratory tract infections (LRTIs) associated with antibiotic resistant biofilm-dwelling and intracellular bacterial pathogens","volume":"227","author":"Islam","year":"2024","journal-title":"Respir Med"},{"key":"2026022412250202000_dkag064-B18","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.2217\/fmb-2018-0216","article-title":"Is synergy the key to treating high-density infections?","volume":"13","author":"Pletzer","year":"2018","journal-title":"Future Microbiol"},{"key":"2026022412250202000_dkag064-B19","doi-asserted-by":"publisher","first-page":"128028","DOI":"10.1016\/j.jhazmat.2021.128028","article-title":"Disinfection of polymicrobial urines by electrochemical oxidation: removal of antibiotic-resistant bacteria and genes","volume":"426","author":"Herraiz-Carbon\u00e9","year":"2022","journal-title":"J Hazard Mater"},{"key":"2026022412250202000_dkag064-B20","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.2147\/IDR.S509016","article-title":"Mechanisms of antimicrobial resistance in Klebsiella: advances in detection methods and clinical implications","volume":"18","author":"Li","year":"2025","journal-title":"Infect Drug Resist"},{"key":"2026022412250202000_dkag064-B21","doi-asserted-by":"publisher","first-page":"e00140-17","DOI":"10.1128\/mBio.00140-17","article-title":"New mouse model for chronic infections by gram-negative bacteria enabling the study of anti-infective efficacy and host-microbe interactions","volume":"8","author":"Pletzer","year":"2017","journal-title":"MBio"},{"key":"2026022412250202000_dkag064-B22","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1080\/17425247.2022.2089111","article-title":"An expert opinion on respiratory delivery of high dose powders for lung infections","volume":"19","author":"Adhikari","year":"2022","journal-title":"Expert Opin Drug Deliv"},{"key":"2026022412250202000_dkag064-B23","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.2147\/IDR.S453025","article-title":"Mechanisms of antibiotic resistance and developments in therapeutic strategies to combat Klebsiella pneumoniae infection","volume":"17","author":"Li","year":"2024","journal-title":"Infect Drug Resist"},{"key":"2026022412250202000_dkag064-B24","doi-asserted-by":"publisher","first-page":"100333","DOI":"10.1016\/j.microb.2025.100333","article-title":"Klebsiella pneumoniae: a growing threat in the era of antimicrobial resistance","volume":"7","author":"Asokan","year":"2025","journal-title":"Microbe"},{"key":"2026022412250202000_dkag064-B25","doi-asserted-by":"publisher","first-page":"1529157","DOI":"10.3389\/fmicb.2025.1529157","article-title":"Mobile genetic elements encoding antibiotic resistance genes and virulence genes in Klebsiella pneumoniae: important pathways for the acquisition of virulence and resistance","volume":"16","author":"Han","year":"2025","journal-title":"Front Microbiol"},{"key":"2026022412250202000_dkag064-B26","doi-asserted-by":"publisher","first-page":"e70077","DOI":"10.1002\/imt2.70077","article-title":"Geographic containment and virulence-resistance trade-offs drive the evolution of hypervirulent Klebsiella pneumoniae","volume":"4","author":"Wu","year":"2025","journal-title":"iMeta"},{"key":"2026022412250202000_dkag064-B27","doi-asserted-by":"publisher","first-page":"e01945-19","DOI":"10.1128\/mBio.01945-19","article-title":"Evolution of outbreak-causing carbapenem-resistant Klebsiella pneumoniae ST258 at a tertiary care hospital over 8 years","volume":"10","author":"Marsh","year":"2019","journal-title":"MBio"},{"key":"2026022412250202000_dkag064-B28","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.jgar.2020.03.023","article-title":"Genomic characteristics of clinically important ST11 Klebsiella pneumoniae strains worldwide","volume":"22","author":"Zhao","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2026022412250202000_dkag064-B29","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12879-023-08156-5","article-title":"The distribution characteristics of global blaOXA-carrying Klebsiella pneumoniae","volume":"23","author":"Meng","year":"2023","journal-title":"BMC Infect Dis"},{"key":"2026022412250202000_dkag064-B30","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1139\/cjm-2024-0032","article-title":"Antimicrobial resistance in Klebsiella pneumoniae: an overview of common mechanisms and a current Canadian perspective","volume":"70","author":"Braun","year":"2024","journal-title":"Can J Microbiol"},{"key":"2026022412250202000_dkag064-B31","doi-asserted-by":"publisher","first-page":"19779","DOI":"10.1038\/s41598-020-75914-9","article-title":"Virulence-determinants and antibiotic-resistance genes of MDR-E. coli isolated from secondary infections following FMD-outbreak in cattle","volume":"10","author":"Algammal","year":"2020","journal-title":"Sci Rep"},{"key":"2026022412250202000_dkag064-B32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1186\/s12920-024-02043-x","article-title":"A systematic review and meta-analysis of carbapenem-resistant Enterobacteriaceae in West Africa","volume":"17","author":"Somda","year":"2024","journal-title":"BMC Med Genomics"},{"key":"2026022412250202000_dkag064-B33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3390\/antibiotics11040503","article-title":"TEM, CTX-M, SHV genes in ESBL-producing Escherichia coli and Klebsiella pneumoniae isolated from clinical samples in a county clinical emergency hospital Romania-predominance of CTX-M-15","volume":"11","author":"Ghenea","year":"2022","journal-title":"Antibiotics"},{"key":"2026022412250202000_dkag064-B34","doi-asserted-by":"publisher","first-page":"1645042","DOI":"10.3389\/fcimb.2025.1645042","article-title":"Global epidemiology and resistance-related mutations of ceftazidime-avibactam-resistant Klebsiella pneumoniae strains","volume":"15","author":"Xie","year":"2025","journal-title":"Front Cell Infect Microbiol"},{"key":"2026022412250202000_dkag064-B35","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jgar.2025.02.020","article-title":"Plasmidome analyses of Klebsiella pneumoniae co-producing blaKPC-2 and blaNDM-1 in Southern Brazil: characterisation of mobile genetic elements","volume":"42","author":"Berdichevski","year":"2025","journal-title":"J Glob Antimicrob Resist"},{"key":"2026022412250202000_dkag064-B36","doi-asserted-by":"publisher","first-page":"e2203593119","DOI":"10.1073\/pnas.2203593119","article-title":"Recurrent emergence of Klebsiella pneumoniae carbapenem resistance mediated by an inhibitory ompK36 mRNA secondary structure","volume":"119","author":"Wong","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026022412250202000_dkag064-B37","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41579-018-0141-x","article-title":"Drug combinations: a strategy to extend the life of antibiotics in the 21st century","volume":"17","author":"Tyers","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"2026022412250202000_dkag064-B38","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jiac.2024.02.007","article-title":"Monotherapy vs combination therapy in patients with Klebsiella pneumoniae bloodstream infection: a systematic review and meta-analysis","volume":"30","author":"Li","year":"2024","journal-title":"J Infect Chemother"},{"key":"2026022412250202000_dkag064-B39","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14787210.2023.2184346","article-title":"Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?","volume":"21","author":"Ardebili","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026022412250202000_dkag064-B40","doi-asserted-by":"publisher","first-page":"e1007726","DOI":"10.1371\/journal.ppat.1007726","article-title":"Heteroresistance: a cause of unexplained antibiotic treatment failure?","volume":"15","author":"Band","year":"2019","journal-title":"PLoS Pathog"},{"key":"2026022412250202000_dkag064-B41","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s42003-021-02052-x","article-title":"The highly dynamic nature of bacterial heteroresistance impairs its clinical detection","volume":"4","author":"Pereira","year":"2021","journal-title":"Commun Biol"},{"key":"2026022412250202000_dkag064-B42","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41579-019-0218-1","article-title":"Mechanisms and clinical relevance of bacterial heteroresistance","volume":"17","author":"Andersson","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"2026022412250202000_dkag064-B43","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.3390\/genes14071426","article-title":"Insight into antibiotic synergy combinations for eliminating colistin heteroresistant Klebsiella pneumoniae","volume":"14","author":"Rajakani","year":"2023","journal-title":"Genes (Basel)"},{"key":"2026022412250202000_dkag064-B44","doi-asserted-by":"publisher","first-page":"e0015221","DOI":"10.1128\/Spectrum.00152-21","article-title":"Combined effect of polymyxin B and tigecycline to overcome heteroresistance in carbapenem-resistant Klebsiella pneumoniae","volume":"9","author":"Tian","year":"2021","journal-title":"Microbiol Spectr"},{"key":"2026022412250202000_dkag064-B45","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.1093\/jac\/dkz257","article-title":"Efficacy of colistin alone and in various combinations for the treatment of experimental osteomyelitis due to carbapenemase-producing Klebsiella pneumoniae","volume":"74","author":"Cr\u00e9mieux","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026022412250202000_dkag064-B46","doi-asserted-by":"publisher","first-page":"106702","DOI":"10.1016\/j.ijantimicag.2022.106702","article-title":"Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae","volume":"61","author":"Davido","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026022412250202000_dkag064-B47","doi-asserted-by":"publisher","first-page":"682239","DOI":"10.3389\/fmicb.2021.682239","article-title":"Heteroresistance to amikacin in carbapenem-resistant Klebsiella pneumoniae strains","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Microbiol"},{"key":"2026022412250202000_dkag064-B48","doi-asserted-by":"publisher","first-page":"e0119923","DOI":"10.1128\/spectrum.01199-23","article-title":"Synergistic effects of polymyxin and vancomycin combinations on carbapenem-and polymyxin-resistant Klebsiella pneumoniae and their molecular characteristics","volume":"11","author":"Nwabor","year":"2023","journal-title":"Microbiol Spectr"},{"key":"2026022412250202000_dkag064-B49","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3390\/antibiotics12020237","article-title":"In vitro and in vivo synergism of fosfomycin in combination with meropenem or polymyxin B against KPC-2-producing Klebsiella pneumoniae clinical isolates","volume":"12","author":"Ribeiro","year":"2023","journal-title":"Antibiotics"},{"key":"2026022412250202000_dkag064-B50","doi-asserted-by":"publisher","first-page":"e0093024","DOI":"10.1128\/aac.00930-24","article-title":"Synergistic antimicrobial combination of third-generation cephalosporins and polymyxin B against carbapenem-polymyxin-resistant Klebsiella pneumoniae: an in vitro and in vivo analysis","volume":"68","author":"Sturaro","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026022412250202000_dkag064-B51","doi-asserted-by":"publisher","first-page":"106344","DOI":"10.1016\/j.ijantimicag.2021.106344","article-title":"Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli","volume":"57","author":"Scudeller","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"2026022412250202000_dkag064-B52","doi-asserted-by":"publisher","first-page":"e0127922","DOI":"10.1128\/aac.01279-22","article-title":"The effect of \u03b2-lactam antibiotics on the evolution of ceftazidime\/avibactam and cefiderocol resistance in KPC-producing Klebsiella pneumoniae","volume":"67","author":"Zhang","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026022412250202000_dkag064-B53","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.2147\/IDR.S411381","article-title":"Microbiologic cure with a simplified dosage of intravenous colistin in adults: a retrospective cohort study","volume":"16","author":"Al-Zubairy","year":"2023","journal-title":"Infect Drug Resist"},{"key":"2026022412250202000_dkag064-B54","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.2147\/IDR.S234211","article-title":"Colistin plus carbapenem versus colistin monotherapy in the treatment of carbapenem-resistant Acinetobacter baumannii pneumonia","volume":"12","author":"Shi","year":"2019","journal-title":"Infect Drug Resist"},{"key":"2026022412250202000_dkag064-B55","doi-asserted-by":"publisher","first-page":"e00246-20","DOI":"10.1128\/AAC.00246-20","article-title":"Polymyxin triple combinations against polymyxin-resistant, multidrug-resistant, KPC-producing Klebsiella pneumoniae","volume":"64","author":"Aye","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026022412250202000_dkag064-B56","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1002\/cpt.2197","article-title":"Evaluation strategies for triple-drug combinations against carbapenemase-producing Klebsiella pneumoniae in an in vitro hollow-fiber infection model","volume":"109","author":"Garcia","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2026022412250202000_dkag064-B57","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13613-023-01153-6","article-title":"Rationale and evidence for the use of new beta-lactam\/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients","volume":"13","author":"Barbier","year":"2023","journal-title":"Ann Intensive Care"},{"key":"2026022412250202000_dkag064-B58","doi-asserted-by":"publisher","first-page":"104874","DOI":"10.1016\/j.jddst.2023.104874","article-title":"Promising treatments for refractory pneumonia caused by multidrug-resistant Klebsiella pneumoniae","volume":"87","author":"Li","year":"2023","journal-title":"J Drug Delivery Sci Technol"},{"key":"2026022412250202000_dkag064-B59","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s40265-019-1055-2","article-title":"Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant gram-negative bacilli","volume":"79","author":"Zhanel","year":"2019","journal-title":"Drugs"},{"key":"2026022412250202000_dkag064-B60","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026022412250202000_dkag064-B61","doi-asserted-by":"publisher","first-page":"3399","DOI":"10.1093\/jac\/dkz318","article-title":"Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case report","volume":"74","author":"Trecarichi","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2026022412250202000_dkag064-B62","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1093\/cid\/ciac078","article-title":"Cefiderocol for the treatment of infections due to metallo-B-lactamase\u2013producing pathogens in the CREDIBLE-CR and APEKS-NP phase 3 randomized studies","volume":"75","author":"Timsit","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2026022412250202000_dkag064-B63","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s40121-023-00773-6","article-title":"Cefiderocol, a siderophore cephalosporin, as a treatment option for infections caused by carbapenem-resistant Enterobacterales","volume":"12","author":"Kaye","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2026022412250202000_dkag064-B64","doi-asserted-by":"publisher","first-page":"e00797-20","DOI":"10.1128\/AAC.00797-20","article-title":"Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against carbapenem-resistant Escherichia coli isolates from the United States and international sites in relation to clonal background, resistance genes, coresistance, and region","volume":"64","author":"Johnston","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2026022412250202000_dkag064-B65","doi-asserted-by":"publisher","first-page":"1048633","DOI":"10.3389\/fcimb.2022.1048633","article-title":"Last resort beta-lactam antibiotics for treatment of New-Delhi metallo-beta-lactamase producing Enterobacterales and other difficult-to-treat resistance in Gram-negative bacteria: a real-life study","volume":"12","author":"Larcher","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"2026022412250202000_dkag064-B66","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3390\/antibiotics11060723","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics"},{"key":"2026022412250202000_dkag064-B67","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/jac\/dkac197","article-title":"Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance","volume":"77","author":"Witt","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"2026022412250202000_dkag064-B68","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"2026022412250202000_dkag064-B69","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/antibiotics13020141","article-title":"Meropenem plus ertapenem and ceftazidime\u2013avibactam plus aztreonam for the treatment of ventilator associated pneumonia caused by pan-drug resistant Klebsiella pneumoniae","volume":"13","author":"Mantzarlis","year":"2024","journal-title":"Antibiotics"},{"key":"2026022412250202000_dkag064-B70","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5603\/ARM.a2020.0195","article-title":"Double carbapenem regimen used as salvage therapy to treat multidrug-resistant Klebsiella pneumoniae causing ventilator-associated pneumonia","volume":"89","author":"Singh","year":"2021","journal-title":"Adv Respir Med"},{"key":"2026022412250202000_dkag064-B71","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1016\/j.jmb.2019.04.002","article-title":"\u03b2-Lactamases and \u03b2-lactamase inhibitors in the 21st century","volume":"431","author":"Tooke","year":"2019","journal-title":"J Mol Biol"},{"key":"2026022412250202000_dkag064-B72","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.jgar.2021.04.001","article-title":"Resistance to ceftazidime\/avibactam in infections and colonisations by KPC-producing Enterobacterales: a systematic review of observational clinical studies","volume":"25","author":"Di Bella","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2026022412250202000_dkag064-B73","doi-asserted-by":"publisher","first-page":"4767","DOI":"10.3390\/ijms24054767","article-title":"Ceftazidime-avibactam (C\/A) resistant, meropenem sensitive KPC-producing Klebsiella pneumoniae in ICU setting: we are what we are treated with?","volume":"24","author":"Corcione","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026022412250202000_dkag064-B74","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1080\/14787210.2023.2151435","article-title":"New advances in management and treatment of multidrug-resistant Klebsiella pneumoniae","volume":"21","author":"Russo","year":"2023","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2026022412250202000_dkag064-B75","doi-asserted-by":"publisher","first-page":"671153","DOI":"10.3389\/fmicb.2021.671153","article-title":"Characterization of tigecycline-heteroresistant Klebsiella pneumoniae clinical isolates from a Chinese tertiary care teaching hospital","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Microbiol"},{"key":"2026022412250202000_dkag064-B76","doi-asserted-by":"publisher","first-page":"dlac121","DOI":"10.1093\/jacamr\/dlac121","article-title":"Effect of ceftazidime\/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae: results from a multicentre retrospective study","volume":"4","author":"Oliva","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2026022412250202000_dkag064-B77","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase\u2013producing K. pneumoniae infections: a retrospective observational multicenter study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026022412250202000_dkag064-B78","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12941-023-00573-3","article-title":"Ceftazidime-avibactam plus aztreonam synergistic combination tested against carbapenem-resistant Enterobacterales characterized phenotypically and genotypically: a glimmer of hope","volume":"22","author":"Taha","year":"2023","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2026022412250202000_dkag064-B79","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1038\/s41598-024-53130-z","article-title":"Next generation antibiotic combinations to combat pan-drug resistant Klebsiella pneumoniae","volume":"14","author":"Kaur","year":"2024","journal-title":"Sci Rep"},{"key":"2026022412250202000_dkag064-B80","doi-asserted-by":"publisher","first-page":"105842","DOI":"10.1016\/j.ijantimicag.2019.10.023","article-title":"Successful treatment of septic shock due to NDM-1-producing Klebsiella pneumoniae using ceftazidime\/avibactam combined with aztreonam in solid organ transplant recipients: report of two cases","volume":"55","author":"Benchetrit","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2026022412250202000_dkag064-B81","doi-asserted-by":"publisher","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026022412250202000_dkag064-B82","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.jmii.2021.02.001","article-title":"Activities of imipenem-relebactam combination against carbapenem-nonsusceptible Enterobacteriaceae in Taiwan","volume":"55","author":"Yang","year":"2022","journal-title":"J Microbiol Immunol Infect"},{"key":"2026022412250202000_dkag064-B83","doi-asserted-by":"publisher","first-page":"e0292722","DOI":"10.1128\/spectrum.02927-22","article-title":"Imipenem-relebactam susceptibility in Enterobacterales isolates recovered from ICU patients from Spain and Portugal (SUPERIOR and STEP studies)","volume":"10","author":"Hern\u00e1ndez-Garc\u00eda","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2026022412250202000_dkag064-B84","doi-asserted-by":"publisher","first-page":"ofab141","DOI":"10.1093\/ofid\/ofab141","article-title":"Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-, cefiderocol-resistant ST-512 Klebsiella pneumoniae\u2013producing KPC-31, a D179Y variant of KPC-3","volume":"8","author":"Tiseo","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2026022412250202000_dkag064-B85","doi-asserted-by":"publisher","first-page":"118915","DOI":"10.1016\/j.ijpharm.2019.118915","article-title":"Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections","volume":"575","author":"Yu","year":"2020","journal-title":"Int J Pharm"},{"key":"2026022412250202000_dkag064-B86","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s40248-018-0149-0","article-title":"Management of severe acute exacerbations of COPD: an updated narrative review","volume":"13","author":"Crisafulli","year":"2018","journal-title":"Multidiscip Respir Med"},{"key":"2026022412250202000_dkag064-B87","doi-asserted-by":"publisher","first-page":"106728","DOI":"10.1016\/j.rmed.2021.106728","article-title":"Bronchiectasis and inhaled tobramycin: a literature review","volume":"192","author":"Elborn","year":"2022","journal-title":"Respir Med"},{"key":"2026022412250202000_dkag064-B88","doi-asserted-by":"publisher","first-page":"102315","DOI":"10.1016\/j.pupt.2024.102315","article-title":"The efficacy and safety of inhaled antibiotics for pneumonia: a systematic review and meta-analysis","volume":"86","author":"Zhang","year":"2024","journal-title":"Pulm Pharmacol Ther"},{"issue":"1\u20132","key":"2026022412250202000_dkag064-B89","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ijpharm.2018.09.014","article-title":"The respiratory delivery of high dose dry powders","volume":"550","author":"Das","year":"2018","journal-title":"Int J Pharm"},{"key":"2026022412250202000_dkag064-B90","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40005-024-00671-0","article-title":"Biocompatible biodegradable polymeric nanocarriers in dry powder inhalers (DPIs) for pulmonary inhalation delivery","volume":"54","author":"Encinas-Basurto","year":"2024","journal-title":"J Pharm Investig"},{"key":"2026022412250202000_dkag064-B91","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1007\/s11947-024-03317-z","article-title":"Effect of spray drying on physicochemical stability and antioxidant capacity of Rosa pimpinellifolia fruit extract-loaded liposomes conjugated with chitosan or whey protein during in vitro digestion","volume":"17","author":"Kasapo\u011flu","year":"2024","journal-title":"Food Bioprocess Technol"},{"key":"2026022412250202000_dkag064-B92","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s11095-021-03094-w","article-title":"Advancement of the infant air-jet dry powder inhaler (DPI): evaluation of different positive-pressure air sources and flow rates","volume":"38","author":"Howe","year":"2021","journal-title":"Pharm Res"},{"key":"2026022412250202000_dkag064-B93","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.3390\/pharmaceutics14122667","article-title":"Dissolution and absorption of inhaled drug particles in the lungs","volume":"14","author":"Eedara","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026022412250202000_dkag064-B94","doi-asserted-by":"publisher","first-page":"484","DOI":"10.3390\/antibiotics12030484","article-title":"Current and emerging inhaled antibiotics for chronic pulmonary Pseudomonas aeruginosa and Staphylococcus aureus infections in cystic fibrosis","volume":"12","author":"Li","year":"2023","journal-title":"Antibiotics"},{"key":"2026022412250202000_dkag064-B95","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.3390\/jcm12103577","article-title":"Efficacy and safety of dry powder antibiotics: a narrative review","volume":"12","author":"de la Rosa-Carrillo","year":"2023","journal-title":"J Clin Med"},{"key":"2026022412250202000_dkag064-B96","doi-asserted-by":"publisher","first-page":"1702052","DOI":"10.1183\/13993003.02052-2017","article-title":"RESPIRE 1: a phase III placebo-controlled randomised trial of ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis","volume":"51","author":"De Soyza","year":"2018","journal-title":"Eur Respir J"},{"key":"2026022412250202000_dkag064-B97","doi-asserted-by":"publisher","first-page":"124309","DOI":"10.1016\/j.ijpharm.2024.124309","article-title":"Inhalable solid lipid nanoparticles of levofloxacin for potential tuberculosis treatment","volume":"660","author":"Paul","year":"2024","journal-title":"Int J Pharm"},{"key":"2026022412250202000_dkag064-B98","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1080\/17425247.2024.2301931","article-title":"The quest to deliver high-dose rifampicin: can the inhaled approach help?","volume":"21","author":"Khadka","year":"2024","journal-title":"Expert Opin Drug Deliv"},{"key":"2026022412250202000_dkag064-B99","doi-asserted-by":"publisher","first-page":"175357","DOI":"10.1016\/j.scitotenv.2024.175357","article-title":"The longitudinal trend and influential factors exploring of global antimicrobial resistance in Klebsiella pneumoniae","volume":"950","author":"Yuan","year":"2024","journal-title":"Sci Total Environ"},{"key":"2026022412250202000_dkag064-B100","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000087686","article-title":"Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa","volume":"73","author":"Lechtzin","year":"2006","journal-title":"Respiration"},{"key":"2026022412250202000_dkag064-B101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13054-020-2763-4","article-title":"Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial","volume":"24","author":"Ben\u00edtez-Cano","year":"2020","journal-title":"Crit Care"},{"key":"2026022412250202000_dkag064-B102","doi-asserted-by":"publisher","first-page":"114078","DOI":"10.1016\/j.addr.2021.114078","article-title":"Overcoming the rising incidence and evolving mechanisms of antibiotic resistance by novel drug delivery approaches\u2013an overview","volume":"181","author":"Lai","year":"2022","journal-title":"Adv Drug Deliv Rev"},{"key":"2026022412250202000_dkag064-B103","doi-asserted-by":"publisher","first-page":"200","DOI":"10.3390\/antibiotics11020200","article-title":"Progress in alternative strategies to combat antimicrobial resistance: focus on antibiotics","volume":"11","author":"Murugaiyan","year":"2022","journal-title":"Antibiotics"},{"key":"2026022412250202000_dkag064-B104","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ijpharm.2018.07.010","article-title":"Composite particle formulations of colistin and meropenem with improved in-vitro bacterial killing and aerosolization for inhalation","volume":"548","author":"Mangal","year":"2018","journal-title":"Int J Pharm"},{"key":"2026022412250202000_dkag064-B105","doi-asserted-by":"publisher","first-page":"106818","DOI":"10.1016\/j.ijantimicag.2023.106818","article-title":"Real-life use of cefiderocol for salvage therapy of severe infections due to carbapenem-resistant Gram-negative bacteria","volume":"62","author":"de la Fuente","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"2026022412250202000_dkag064-B106","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1093\/cid\/ciaa1410","article-title":"Cefiderocol as rescue therapy for Acinetobacter baumannii and other carbapenem-resistant Gram-negative infections in intensive care unit patients","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026022412250202000_dkag064-B107","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/antibiotics11070904","article-title":"Cefiderocol for carbapenem-resistant bacteria: handle with care! A review of the real-world evidence","volume":"11","author":"Sansone","year":"2022","journal-title":"Antibiotics"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag064\/67092600\/dkag064.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/81\/3\/dkag064\/67092600\/dkag064.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T17:25:11Z","timestamp":1771953911000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/doi\/10.1093\/jac\/dkag064\/8496198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":107,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkag064","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,2,2]]},"article-number":"dkag064"}}